Senior Staff

Scientific and Business Development Team

Proteomics International has an unparalleled scientific and commercial team from a diverse range of backgrounds.  The team has skills in all aspects of protein chemistry encompassing the cutting edge of mass spectrometry to traditional methods and more.

Dr Richard Lipscombe (Managing Director)

Richard has extensive experience in analysing biomolecules by proteomics techniques, in particular mass spectrometry, including over 25 years research experience in academic and commercial organisations. As a founding Director and Managing Director of Proteomics International Richard has overseen the commercial and technical development of the organisation.  Previously he was Manager of the core Protein Analysis Facility at the University of Western Australia, following a post-doctoral position at the Institute for Child Health Research. He is company trained in the use of MALDI-TOF MS and LC/MS/MS (including TOF/TOFs and ion-traps), and further expertise/training in Edman sequencing, peptide synthesis, and robotics for proteomics.

Qualifications
1995 PhD (Immunology), University of London (Institute of Child Health)
1991 Certificate in Immunology, Kings College, University of London
1990 MA and BA (Chemistry), Corpus Christi College, Oxford University

Ms Jacqueline Gray (Chief Financial Officer)

Jacqueline has over 25 years of experience as Senior Finance Executive for multiple global companies, based in London, and several emerging, high growth companies in the medical technology, SaaS, digital marketing, e commerce, retail and renewables sectors, based in Perth. She has a successful track record with developing & implementing strategy, building high performance teams, M&A and post-merger integration. Her previous roles include Finance Director of the Economist Intelligence Unit, senior roles with BBC Worldwide, and Financial Controller of several hospitals and medical facilities for Healthcare of Australia.

Qualifications
Chartered Accountant, Institute of Chartered Accountants
Graduate Diploma in Applied Corporate Governance, Governance Institute of Australia
Bachelor of Business (Accounting), Edith Cowan University

Phillip Prather (Chief Commercial Officer)

As the Chief Commercial Officer for Proteomics International, Phillip is responsible for Global Sales, Marketing, and Customer Engagement activities. Phillip brings extensive leadership in the global medical devices industry, particularly in developing new markets and successfully launching products for innovative companies including Cochlear, QIAGEN, Philips, Medtronic, and Leo Cancer Care.

Recently, Phillip managed global operations at Down Under Enterprises, achieving global leadership in Sustainability and a recognised leader in functional natural ingredients. He also served as the Chair of the Board of Directors of ATTIA Ltd, the peak industry body for iconic Australian Tea Tree Oil.

Qualifications
Australian Institute of Company Directors (AICD)
Master of Commerce (Marketing), University of New South Wales
GradDip in Finance, Case Western Reserve University
Bachelor’s degree, Biology (Honours in Neurobiology, College of Medicine) and Economics, University of Vermont

Mr Chuck Morrison (Head of Business Development)

Chuck has over 35 years of Business Development & Corporate Strategy experience in the life sciences, diagnostic and biotechnology industries. He has held several senior management positions with NEN Life Sciences and DuPont Medical before focusing his last 15 years in corporate development at PerkinElmer. Chuck has successfully executed several strategic licensing, distribution & partnership deals and has completed multiple global acquisitions. Mr. Morrison currently serves on the Board of Directors with Avisa Pharma and XCR Diagnostics as well as a Senior Advisor for Outcome Capital. Chuck is based in Boston, Massachusetts, USA.

Qualifications
MBA (Finance & Marketing), Boston University, Massachusetts, USA
BA (Chemistry), College of the Holy Cross, Massachusetts, USA

Dr Scott Bringans (Head of Research)

Scott is responsible for all Research areas within Proteomics International. This involves oversight of Biomarker discovery and development projects encompassing PromarkerD, PI’s predictive test for diabetic nephropathy. Alongside the biomarker research program is the development and implementation of novel methods for examining biological systems (particularly venoms) for discovery of novel therapeutic peptides where genomic/ proteomic information is unavailable or incomplete.   He also leads the development of new chromatographic and mass spectrometric methods for handling of complex biological samples for analysis and investigation.

Scott has a commercial background as proteomics scientist and mass spectrometry specialist at a New Zealand based R&D company, now part of AgResearch. This was preceded by a Post-Doctoral Fellowship at the National Cancer Institute, USA, looking at bioactive protein isolation, purification and identification of both anti-cancer and anti-HIV leads from marine sources. Scott’s skills are wide ranging and include expertise with mass spectrometers, liquid chromatography, assay development and bioinformatic analysis.

Qualifications
PhD, Department of Chemistry, University of Canterbury
BSc (Hons), Department of Chemistry, University of Canterbury

Dr Pearl Tan (Head of Product Development)

Pearl is responsible for coordinating and ensuring the commercial delivery of PromarkerD and the Promarker™ pipeline. Pearl has extensive experience in management and research commercialisation. Her previous roles include Chief Operating Officer of Proteomics International, Head of Logistics, and leading the commercialisation of the patented 2-tag technology (used to measure oxidative stress). Pearl has a background in research and completed her PhD in Biochemistry and Molecular Biology at The University of Western Australia. She has been with Proteomics International since 2014.

Qualifications
PhD (Research), Biochemistry and Molecular Biology, UWA
BSc with honours in Biochemistry, UWA, Australia
BSc, Molecular Biology and Biotechnology, UWA, Australia

Dr Kirsten Peters (Head of Clinical Studies)

Kirsten has over 15 years of experience in clinical and genetic epidemiology. Kirsten leads the clinical studies and biostatistics team at Proteomics International, responsible for the development and validation of PromarkerD and diagnostics in the Promarker™ pipeline. She has been with the company for over 10 years and has been a Consultant at the University of Western Australia for 15 years. Kirsten has extensive experience in data analysis and has co-authored over 40 peer-reviewed journal articles.

Qualifications
PhD (Research), Medical Sciences, JCSMR, ANU, Australia
BSc with honours in Medical Sciences, UON, Australia
BSc in Molecular Biology and Medical Sciences, UON, Australia

Dr Johan Conradie (Clinical Pathologist)

Johan is a Chemical Pathologist with over 21 years of experience in clinical biochemistry and toxicology, spanning both South Africa and Australia. He began his career after completing an Bachelor of Medicine and Surgery (MBChB) at the University of Pretoria in 1998 and specialised in Chemical Pathology at the University of Witwatersrand, earning his FCPath (Chem) in 2005. He gained his FRCPA in 2008 and later completed an MBA at the University of Western Australia in 2019.

At Proteomics International, Johan supports the Company’s accreditation processes, ensuring compliance with ISO 15189 and contributing to innovative diagnostics that improve patient outcomes. His professional interests include computational and digital pathology, toxicology, and advancing laboratory standards to align with global best practices.

In addition to his work at Proteomics International, Johan serves as the Medical Director of Western Diagnostic Pathology and holds an Adjunct Associate Professorship at the University of Notre Dame Fremantle. He is actively involved in teaching, conducting technical assessments for NATA, and serving as an examiner for the Royal College of Pathologists of Australasia (RCPA). Johan has delivered numerous presentations and contributed to academic publications on topics such as diagnostic trends, endocrinology, and AI in pathology.

Qualifications
2019 Master of Business Administration, UWA, Australia
2008 FRCPA, Royal College of Pathologists of Australasia
2005 FCPath(Chem), University of Witwatersrand, South Africa
1998 Bachelor of Medicine and Surgery (MBChB), University of Pretoria, South Africa

Ms Sreeja Sony (Business Manager – Analytical Services)

Sreeja brings 14 years of Sales & Business Development experience in the medical technology and pharmaceutical sectors. She has handled operations, logistics, technical support and purchasing activities in her previous roles. Sreeja has substantial experience selling life sciences services, consumables and instruments to a wide range of clients across the biopharma space.

Sreeja joined Proteomics International in 2016 and was recently appointed to Business Manager of the company’s Analytical Services business unit.

Qualifications
Post Graduate Diploma in Business Management-Marketing, NMIMS, India
MSc in Biotechnology, PTU, India
BSc in Biotechnology, Bangalore University, India

Ms Hitormi Lim (Laboratory Operations Manager)

Hitormi has over 10 years of experience in laboratory management and technical research at Proteomics International. Starting as a Research Scientist, Hitormi specialised in project management and technical research, developing methods and optimising quality controls for research projects and analytical services. She then progressed to Laboratory Manager, overseeing all laboratory activities, including resource management, accreditation, and quality management systems. She also led technical staff specialised in biomarker discovery and validation in the Promarker™ Pipeline. Recently promoted to Operations Manager of the Laboratory, Hitormi is outcome-driven and focuses on effective leadership, embracing the mantra ‘Bring the best out of people’, both professionally and personally.

Qualifications
BSc in Biochemistry, Molecular Biology and Pharmacology, UWA, Australia